Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.44 |
| ▸ | MAT2A | P31153 | 10/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13665487 | 0.88 | KDM4E (0.39) | MAT2AALDH1A1KDM4ELMNAGAA | |
| SCHEMBL13654457 | 0.87 | MAT2A (0.43) | CYP11B2CYP11B1MAT2APRMT5CYP3A4 | |
| SCHEMBL13665490 | 0.86 | KDM4E (0.42) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL13654432 | 0.82 | KCNH2 (0.43) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL13665767 | 0.82 | MAPT (0.40) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL13663439 | 0.82 | CYP11B1 (0.36) | CYP11B2CYP11B1ALDH1A1KDM4ELMNA | |
| SCHEMBL13665759 | 0.81 | KDM4E (0.39) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL13665753 | 0.81 | SLC6A4 (0.40) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL13665755 | 0.79 | USP14 (0.43) | CYP3A4CYP1A2ALDH1A1KDM4ELMNA | |
| SCHEMBL13654582 | 0.79 | CYP11B1 (0.34) | CYP11B2CYP11B1ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338447-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009120717-A2 | PYRIDO [3, 4-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP11B2 2181/4885CYP11B1 2308/4885MAT2A 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.